CME Presentations

MG


Presentations


Speakers

  • James Howard Jr., MD, FAAN

    James Howard Jr., MD, FAAN

    James Howard Jr., MD, FAAN

    Professor of Neuromuscular Disease

    James Howard, MD, FAAN, is the former James F Howard Distinguished Professor of Neuromuscular Disease and the prior Chief of the Neuromuscular Disorders Section at UNC. Currently, he’s a Professor of Neurology, Medicine, and Allied Health at UNC, Chapel Hill School of Medicine and directs the Myasthenia Gravis (MG) Clinical Trials and Translational Research Unit at UNC. A practicing neurologist for over 41 years with a focus on MG and EMG, Dr. Howard is a leading expert in MG and has authored more than 110 abstracts, 150 articles, 35 book chapters, and 3 books. He was the 2019 recipient of the European Academy of Neurology Investigator Award and is frequently invited to lecture on MG at meetings. Dr. Howard is a member of the NIH-funded rare disease clinical research network, MGNet.
  • Jeffrey Guptill, MD, MA, MHS

    Jeffrey Guptill, MD, MA, MHS

    Jeffrey Guptill, MD, MA, MHS

    Associate Professor of Neurology

    Jeffrey Guptill, MD, MA, MHS, is an Associate Professor of Neurology at Duke University School of Medicine and Director of the Duke Early Phase Clinical Research Unit. He serves as a member of the executive committee for MGNet, the NIH-funded rare disease clinical research network for myasthenia gravis (MG). In this role, he chairs the natural history study and career enhancement core of the network. Dr. Guptill’s research interests include the development of diagnostic and predictive biomarkers and conducting clinical trials of novel therapeutics for the treatment of inflammatory neuromuscular diseases. Moreover, Dr. Guptill serves as chair on the Medical Scientific Advisory Board of the Myasthenia Gravis Foundation of America and leads the NeuroIMmunology BiosampLE (NIMBLE) network.

CME Information

PIM Logo PQH Logo

Evolving Treatment Approaches for Generalized Myasthenia Gravis to Reduce Disease Burden and Improve Daily Living

Jointly provided by Postgraduate Institute for Medicine and PlatformQ Health Education, LLC working in collaboration with National Organization for Rare Disorders, Inc (NORD), and Myasthenia Gravis Foundation of America, Inc (MGFA).

ACKNOWLEDGEMENT

Supported by an independent educational grant from argenx.

TUITION

Complimentary

JOINT ACCREDITATION STATEMENT

In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and PlatformQ Health Education, LLC. Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

LIVE CREDIT DESIGNATION STATEMENT

The Postgraduate Institute for Medicine designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. AMA PRA Category 1 Credits™ claimed by physicians attending live events certified and organized in the United States for AMA PRA Category Credits™ can be claimed through the agreement on mutual recognition of credits between UEMS and AMA, considered as being equal to the European Continuous Medical Education Credits (ECMEC®) granted by the UEMS. One AMA PRA Category 1 Credit™ is equivalent to one (1) hour of European EACCME Credit (ECMEC®); therefore, up to 1.0 ECMEC® Credits are available.

ENDURING CREDIT DESIGNATION STATEMENT

The Postgraduate Institute for Medicine designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. AMA PRA Category 1 Credits™ claimed by physicians participating in e-learning programs certified by accredited providers in the United States can be claimed through the agreement on mutual recognition of credits between UEMS and AMA, considered as being equal to the European Continuous Medical Education Credits (ECMEC®) granted by the UEMS. One AMA PRA Category 1 Credit™ is equivalent to one (1) hour of European EACCME Credit (ECMEC®); therefore, up to 1.0 ECMEC® Credits are available.

DATE OF RELEASE/EXPIRATION

Live Activity
Tuesday, November 30, 2021 at 1:00-2:00pm EST

Enduring Material
November 30, 2021 - November 30, 2022.

LEARNING OBJECTIVES

At the conclusion of this activity, participants will be able to:
  • Describe the impact of comorbidities on the burden of disease, QoL, and selection of personalized treatment for patients with gMG
  • Define the profiles of patients who could benefit from emerging targeted treatment options for gMG based on the results of antibody testing, limitations of currently available treatment options, and comorbidities
  • Summarize the mechanism of action, efficacy, safety, and place in therapy of new and emerging targeted treatment options for gMG
  • Explain how current management of gMG with available treatments drives up healthcare costs and negatively impacts patients’ QoL

TARGET AUDIENCE

The intended audience for this activity program are neuromuscular, neuroimmunology, neuro-ophthalmology and neurology specialists, along with advance care practitioners, such as NPs, PharmDs/RPhs, and Pas.

ESTIMATED TIME TO COMPLETE

This activity should take approximately 1 hour to complete.

METHOD OF PARTICIPATION

There are no fees to participate in this activity. To participate in the activity, go to www.NeuroSeriesLive.com and www.RareDiseaseLive.com. To receive credit, participants must (1) read the target audience, learning objectives, and disclosure statements, (2) complete the educational activity online, and (3) complete the post-test and activity evaluation. To receive AMA PRA Category 1 Credit™, participants must receive a minimum score of 70% on the post-test.

HARDWARE/SOFTWARE REQUIREMENTS

Participants will need a computer with a recent version of Adobe Flash installed, as well as an internet connection sufficient for streaming media.

DISCLOSURE OF CONFLICTS OF INTEREST

Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

Name of Faculty or Presenter Reported Financial Relationship
James F. Howard Jr., MD
Professor of Neuromuscular Disease
Professor of Neurology & Medicine
The University of North Carolina
Chapel Hill, NC

Contracted Research: Alexion Pharmaceuticals, argenx BVBA, the Centers for Disease Control and Prevention (Atlanta, GA, USA), the Myasthenia Gravis Foundation of America, the Muscular Dystrophy Association, the National Institutes of Health (including the National Institute of Neurological Disorders and Stroke and the National Institute of Arthritis and Musculoskeletal and Skin Diseases), PCORI, Ra Pharmaceuticals (now UCB), Regeneron Pharmaceuticals and Takeda Pharmaceuticals; Honoraria from Alexion Pharmaceuticals, argenx BVBA, Immunovant Inc., Ra Pharmaceuticals (now UCB), Regeneron Pharmaceuticals, Sanofi US and Viela Bio Inc. (now Horizon Therapeutics)
Non-financial support: Alexion Pharmaceuticals, argenx BVBA, Ra Pharmaceuticals (now UCB) and Toleranzia AB
Jeff Guptill, MD, MA, MHS, FAAN
Associate Professor
Director, Duke Early Phase Clinical Research Unit
Duke Clinical Research Institute (DCRI)
Department of Neurology - Neuromuscular Medicine
Duke University Medical Center
Consulting Fees (e.g., advisory boards): Alexion, Apellis, Argenx, Becton Dickinson, Cabaletta, Grifols, Immunovant, Jacobus Pharmaceuticals, Janssen, Momenta, Piedmont Pharmaceuticals, Ra Pharma, Regeneron, Toleranzia, and UCB
Contracted Research: Argenx, Centers for Disease Control and Prevention, Janssen, Myasthenia Gravis Foundation of America, NIH (NIAID, NINDS, NIMH), Takeda, and UCB Pharma

The planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:
Name of Planner or Manager Reported Financial Relationship
Carole Drexel
Medical Director
PlatformQ Health Education, LLC
None

The PIM planners and managers have nothing to disclose.

The following PlatformQ Health Education, LLC planner, Bridget Griffin, hereby states that she or her spouse/life partner do not have any financial relationships or relationships to products or devices with any commercial interest related to the content of this activity of any amount during the past 12 months.

DISCLOSURE OF UNAPPROVED/OFF LABEL USE (if applicable):

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

DISCLAIMER:

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

CONTACT INFORMATION

Accreditation Support:
Please contact the Postgraduate Institute for Medicine at inquiries@pimed.com.

Technical Support:
For any technical issues or issues with your CME Certificate, please contact NeuroSeriesLive.com at 1-877-394-1306 or at Info@NeuroSeriesLive.com.